PF07104091

CAS No. 2460249-19-6

PF07104091( PF-07104091 )

Catalog No. M28851 CAS No. 2460249-19-6

PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 915 In Stock
2MG 519 In Stock
5MG 824 In Stock
10MG 1207 In Stock
25MG 1796 In Stock
50MG 2372 In Stock
100MG 3190 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PF07104091
  • Note
    Research use only, not for human use.
  • Brief Description
    PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
  • Description
    PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    PF-07104091
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2460249-19-6
  • Formula Weight
    404.46
  • Molecular Formula
    C19H28N6O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C(=O)C1=CC(COC)=NN1C)C2=CC(=NN2)[C@@H]3C[C@H](OC(NC(C)C)=O)CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yamaguchi T, et al. Determination of 7-chloro-3-(4-methyl-1-piperazinyl)-4h-1,2,4-benzothiadiazine-1,1-dioxide (DU-717) in plasma using electron-capture gas chromatography. J Chromatogr. 1978 Oct 11;160(1):181-90.
molnova catalog
related products
  • Ro-3306

    RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.

  • CDK5 inhibitor 20-22...

    CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9.

  • Dalpiciclib

    Dalpiciclib is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4?nM and 9.9?nM, respectively.